MRI data and genomic data are telling us different things about prostate cancer risk

A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …

FDA approves the first 7 T MRI device for clinical use in the US

So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …

The role of mpMRI in monitoring of men on active surveillance

At least one paper has stated that some 40 percent of men diagnosed with low-risk prostate cancer here in the US are now being initially managed on active surveillance. If active surveillance is being done properly, this is a good thing! However, … READ MORE …

What’s luminal water imaging, and do we need to care?

Two recent papers by Sabouri et al. have suggested that a new MRI techique known as “luminal water imaging” may be able to improve the ability of MR scans to identify and grade prostate cancer prior to biopsy. … READ MORE …

“The best” type of biopsy using mpMRI guidance to target the lesions

There have been suggestions that guided biopsies on the basis of multiparametric MRI (mpMRI) data are most accurate when done using so-called “in-bore” or “in-gantry” biopsies as opposed to mpMRI/TRUS fusion-guided biopsies. … READ MORE …

The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

MRI as a means of screening for prostate cancer? Probably not!

A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …

Serial mpMRIs instead of serial biopsies for men on active surveillance

The role of baseline and repeat multiparametric MRI (mpMRI) scanning as a substitute for repeat biopsies in the initial evaluation and ongoing management of men on active surveillance continues to evolve. … READ MORE …

The evolving role of MRI imaging in undiagnosed prostate cancer

As we have been pointing out for a while, the actual and potential roles for the use of multiparametric MRI (mpMRI) scanning in the diagnosis of prostate cancer is changing, and quite fast too. … READ MORE …

The role of 3 T mpMRI in monitoring men on active surveillance

A newly published paper in the American Journal of Roetgenology provides an early data set on the application of 3 T multiparameric MRI scans in monitoring men on active surveillance (as opposed to the use of serial biopsies). … READ MORE …

PROMIS study endorses mpMRI prior to prostate biopsy for many patients

The PROMIS study is a UK-based study designed to confirm earlier data suggesting that having a multiparametric MRI (mpMRI) scan could really help to decide which men needed a prostate biopsy because they really did or didn’t have prostate cancer. … READ MORE …

New consensus statement on monitoring for prostate cancer risk after a first, negative biopsy

There has been no really clear and formal guidance available on how to monitor patients for risk of prostate cancer after a first, negative, standard, 12-core, systematic biopsy. New guidance from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) may be helpful in addressing this situation. … READ MORE …

How do mpMRI and MRI/TRUS fusion biopsies actually work?

As our regular readers will be well aware, the combination of multiparametric MRI (mpMRI) data with transrectal ultrasound (TRUS)-guided biopsy techniques are rapidly becoming more common in both the diagnosis of prostate cancer and in monitoring risk for prostate cancer in men on active surveillance protocols. … READ MORE …

mpMRIs, MRI/TRUS fusion-guided biopsies, and systematic biopsies in monitoring of men on active surveillance

A new article in the Journal of Urology has provided us with some initial insight into the value of multiparametric MRIs (mpMRIs) in monitoring progression of patients on active surveillance protocols. … READ MORE …

PCA3, mpMRI, targeted biopsies, and risk for diagnosis of prostate cancer

The degree to which the PCA3 test is a useful tool in assessment of risk for clinically significant prostate cancer prior to biopsy has never, really, been entirely clear. … READ MORE …